Cristina F Contreras1, Christine S Higham2, Astrid Behnert3, Kailyn Kim4, Elliot Stieglitz3, Sarah K Tasian1,5. 1. Children's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, Philadelphia, Pennsylvania. 2. San Francisco Benioff Children's Hospital and School of Medicine, Pediatrics, Division of Pediatric Bone Marrow Transplantation, University of California, San Francisco, California. 3. San Francisco Benioff Children's Hospital and School of Medicine, Pediatrics, Division of Hematology-Oncology, University of California, San Francisco, California. 4. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania. 5. Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: The treatment paradigm for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (rrALL) has been revolutionized given recent clinical trials demonstrating remarkable success of immunotherapies and leading to drug approvals by United States and European agencies. We report experience with commercial blinatumomab and inotuzumab use at two North American pediatric oncology centers in children and adolescents/young adults with B-ALL. PROCEDURE: Patients 0-25 years old treated with the CD19 × CD3 bispecific T cell-engaging antibody blinatumomab and/or the CD22 antibody-drug conjugate inotuzumab from January 1, 2010, to June 1, 2018, were eligible. Disease status included relapsed B-ALL in second or greater relapse, primary chemotherapy-refractory B-ALL, or B-ALL complicated by severe infection precluding delivery of conventional chemotherapy. RESULTS: We identified 27 patients who received blinatumomab and/or inotuzumab outside of clinical trials during the study period. Four of the 13 patients (31%) with relapsed disease achieved minimal residual disease (MRD)-negative remission, and five patients (39%) underwent hematopoietic stem cell transplant (HSCT). In the 12 patients with primary chemorefractory B-ALL treated with immunotherapy, 11 (92%) achieved MRD-negative remission as assessed by flow cytometry; 10 patients (83%) underwent subsequent HSCT. Two patients with B-ALL in MRD-negative remission received blinatumomab due to severe infection and remained in remission after chemotherapy continuation. CONCLUSIONS: Blinatumomab and inotuzumab can induce deep remissions in patients with rrALL and facilitate subsequent HSCT or other cellular therapies. Blinatumomab can also serve as an effective bridging therapy during severe infection. The optimal timing, choice of immunotherapeutic agent(s), and duration of responses require further investigation via larger-scale clinical trials.
BACKGROUND: The treatment paradigm for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (rrALL) has been revolutionized given recent clinical trials demonstrating remarkable success of immunotherapies and leading to drug approvals by United States and European agencies. We report experience with commercial blinatumomab and inotuzumab use at two North American pediatric oncology centers in children and adolescents/young adults with B-ALL. PROCEDURE: Patients 0-25 years old treated with the CD19 × CD3 bispecific T cell-engaging antibody blinatumomab and/or the CD22 antibody-drug conjugate inotuzumab from January 1, 2010, to June 1, 2018, were eligible. Disease status included relapsed B-ALL in second or greater relapse, primary chemotherapy-refractory B-ALL, or B-ALL complicated by severe infection precluding delivery of conventional chemotherapy. RESULTS: We identified 27 patients who received blinatumomab and/or inotuzumab outside of clinical trials during the study period. Four of the 13 patients (31%) with relapsed disease achieved minimal residual disease (MRD)-negative remission, and five patients (39%) underwent hematopoietic stem cell transplant (HSCT). In the 12 patients with primary chemorefractory B-ALL treated with immunotherapy, 11 (92%) achieved MRD-negative remission as assessed by flow cytometry; 10 patients (83%) underwent subsequent HSCT. Two patients with B-ALL in MRD-negative remission received blinatumomab due to severe infection and remained in remission after chemotherapy continuation. CONCLUSIONS: Blinatumomab and inotuzumab can induce deep remissions in patients with rrALL and facilitate subsequent HSCT or other cellular therapies. Blinatumomab can also serve as an effective bridging therapy during severe infection. The optimal timing, choice of immunotherapeutic agent(s), and duration of responses require further investigation via larger-scale clinical trials.
Authors: Amy K Keating; Nathan Gossai; Christine L Phillips; Kelly Maloney; Kristen Campbell; Andrew Doan; Deepa Bhojwani; Michael J Burke; Michael R Verneris Journal: Blood Adv Date: 2019-07-09
Authors: Wanda L Salzer; Michael J Burke; Meenakshi Devidas; Si Chen; Lia Gore; Eric C Larsen; Michael Borowitz; Brent Wood; Nyla A Heerema; Andrew J Carroll; Joanne M Hilden; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger Journal: Cancer Date: 2017-12-19 Impact factor: 6.860
Authors: Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: Patrick Brown; Gerhard Zugmaier; Lia Gore; Catherine A Tuglus; Arend von Stackelberg Journal: Br J Haematol Date: 2019-12-03 Impact factor: 6.998
Authors: Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian Journal: Lancet Oncol Date: 2014-12-16 Impact factor: 41.316
Authors: Martha Wadleigh; Paul G Richardson; David Zahrieh; Stephanie J Lee; Corey Cutler; Vincent Ho; Edwin P Alyea; Joseph H Antin; Richard M Stone; Robert J Soiffer; Daniel J DeAngelo Journal: Blood Date: 2003-05-08 Impact factor: 22.113
Authors: K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh Journal: Leukemia Date: 2008-09-25 Impact factor: 11.528
Authors: Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani Journal: N Engl J Med Date: 2016-06-12 Impact factor: 91.245
Authors: Deepa Bhojwani; Richard Sposto; Nirali N Shah; Vilmarie Rodriguez; Constance Yuan; Maryalice Stetler-Stevenson; Maureen M O'Brien; Jennifer L McNeer; Amrana Quereshi; Aurelie Cabannes; Paul Schlegel; Claudia Rossig; Luciano Dalla-Pozza; Keith August; Sarah Alexander; Jean-Pierre Bourquin; Michel Zwaan; Elizabeth A Raetz; Mignon L Loh; Susan R Rheingold Journal: Leukemia Date: 2018-09-28 Impact factor: 11.528
Authors: Giuliana Beneduce; Antonia De Matteo; Pio Stellato; Anna M Testi; Nicoletta Bertorello; Antonella Colombini; Maria C Putti; Carmelo Rizzari; Simone Cesaro; Monica Cellini; Elena Barisone; Fara Petruzziello; Giuseppe Menna; Rosanna Parasole Journal: Cancers (Basel) Date: 2022-01-15 Impact factor: 6.639